AgenDx Biosciences
South Bend · Founded 2014
About AgenDx Biosciences
AgenDx is an early stage molecular diagnostics company developing a revolutionary cost-effective molecular diagnostics platform. Their novel technology allows simple molecular diagnostic lab-quality testing. With a quick sample-to-answer in minutes, their platform is positioned to transform where and how disease is detected and treated. Their platform accommodates a wide range of nucleic-acid based tests for infectious disease, cancer, and other chronic conditions including cardiovascular disease and arthritis. Their initial focus is to prove the AgenDx technology by developing tests for aiding physician’s treatment decisions for pancreatic cancer. Their platform is designed for operation by untrained users in clinical settings near the patient. The sample is collected and inserted into a disposable cartridge. A control system automates and runs the test. Clear results will be displayed and transmitted. Their proprietary system will accommodate any biological sample, including blood, saliva, and tissue.
Company Facts
- Founded: 2014
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.5M
- Funding stage: Seed
- Last round: Seed (Feb 2018)
- Website: https://www.agendxbio.com/
- Phone: [email protected]
Industries & Categories
Clinical Trials, Health Diagnostics
Canonical: https://fsome.com/organization/agendx-biosciences-172537 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.